Chagas

AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights

Retrieved on: 
Thursday, November 9, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MAC, Global health, Pivotal, Entrepreneurship, Therapy, Chagas disease, Investment, Clinical trial, Bill, Administration, Insurance, Patient, IDSA, NTM, AN2, University, Infection, Conference, Partnership, R, Research and development, Boron, Malaria, Poster, Melioidosis, Tuberculosis, Pharmaceutical industry, Life insurance, Pfizer, Chagas, Wellcome

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended September 30, 2023.

Key Points: 
  • AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended September 30, 2023.
  • “We are incredibly proud of the significant milestones achieved recently and over the past quarter.
  • There is an urgent need for more effective, novel, oral agents for this difficult-to-treat disease,” said Eric Easom, Co-Founder, President and Chief Executive Officer.
  • This resulted in aggregate gross proceeds to the Company of approximately $70.0 million, before deducting underwriting discounts and commissions and offering expenses.

AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease

Retrieved on: 
Wednesday, October 18, 2023
Health, Infectious Diseases, General Health, Research, Science, Pharmaceutical, Biotechnology, Primate, IND, Human, Chagas disease, Infection, Entrepreneurship, University, Tropics, Risk, Partnership, University of Georgia, Therapy, AN2, Pharmaceutical industry, Chagas, Pfizer, Wellcome

These boron-based molecules were originally discovered by researchers at Anacor Pharmaceuticals, Inc. (a wholly owned subsidiary of Pfizer) and the University of Georgia, with grant funding from Wellcome.

Key Points: 
  • These boron-based molecules were originally discovered by researchers at Anacor Pharmaceuticals, Inc. (a wholly owned subsidiary of Pfizer) and the University of Georgia, with grant funding from Wellcome.
  • The lead compound under this series, AN2-502998 (formerly known as AN15368), was discovered in close collaboration with Professor Rick Tarleton, Ph.D., University of Georgia, an expert in Chagas disease and Trypanosoma cruzi biology.
  • To date, preclinical activities have been supported using non dilutive grant funding from Wellcome and are conducted in partnership with Professor Tarleton.
  • I am optimistic that AN2-502998 has the potential to be a solution for those infected with T. cruzi and at risk for development of debilitating and life-threatening Chagas disease.”

Africa In Vitro Diagnostics Market Report 2023: A $1.78 Billion Market by 2029 - Key Market Players' Increasing Investments Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Monday, April 3, 2023
Health, Biotechnology, Prevalence, HIV, COVID-19, Chagas, Infection, Chagas disease, Hospital, Fever Dream, IVD, Conditional sentence, Diagnosis, Geography, Medical device, Pharmaceutical industry

Following a detailed secondary and primary research and an in-depth analysis of the market scenario, the report provides the key drivers, restraints, challenges, and opportunities in the Africa IVD market.

Key Points: 
  • Following a detailed secondary and primary research and an in-depth analysis of the market scenario, the report provides the key drivers, restraints, challenges, and opportunities in the Africa IVD market.
  • Based on product category, in 2022, the reagents, assays, and kits segment is expected to account for the largest share of the Africa IVD market.
  • Based on technology, in 2022, the immunoassay segment is expected to account for the largest share of the Africa IVD market.
  • Based on application, in 2022, the infectious diseases segment is expected to account for the largest share of the Africa IVD market.

Predicting the Next Emerging Disease Requiring In Vitro Diagnostics (IVDs)

Retrieved on: 
Wednesday, October 12, 2022
Chagas, Kalorama, Mosquito control, OraSure Technologies, Method, Infection, Ortho Clinical Diagnostics, Tuberculosis, BGI, Bird, BD (company), Roche, Rift Valley fever, CCHF, Dengue fever, SD, InBios, Spider, World, Qiagen, Marketing, IVD, Siemens Healthineers, World Health Organization, Nipa, Yellow fever, Adult, Lassa fever, Thermo Fisher Scientific, Cepheid variable, Bass, TB, Abbott, Pharmaceutical industry, Vaccine, Chikungunya, West Nile virus, Malaria, Turtle, Bruker, Goldfish, Ross River virus

ARLINGTON, Va., Oct. 12, 2022 /PRNewswire-PRWeb/ -- Kalorama estimates a $3.7 billion market for emerging diseases. This market is expected to grow to $4.9 billion in 2026. This is based on its recent report "Emerging Infectious Disease Market Trends, 2022."

Key Points: 
  • ARLINGTON, Va., Oct.12, 2022 /PRNewswire-PRWeb/ -- Kalorama estimates a $3.7 billion market for emerging diseases.
  • This is based on its recent report " Emerging Infectious Disease Market Trends, 2022 ."
  • For many mosquito-borne illnesses, there is no vaccine and little in the way of treatment as the infections are viral.
  • Non mosquito-spread diseases of concern include: Tuberculosis, Chagas, Lyme Disease Marburg virus, Rift Valley Fever, Ebola, Ross River Virus, CCHF, Nipah and Lassa Fever.

7 Hills Pharma Receives $3MM SBIR Grant from NIAID to Accelerate Novel Vaccine Combination Against Chagas Disease

Retrieved on: 
Monday, August 1, 2022
Vaccine, Parasitism, University, GLOBE, Research, Chagas disease, Arrhythmia, CEO, National Institute of Allergy and Infectious Diseases, National Institute, Risk, Infection, Integrin, Howard Brody, Cancer, Technology, Galveston National Laboratory, UTMB, Heart failure, Death, Korea Disease Control and Prevention Agency, Microbiology, Center, Trypanosoma cruzi, Pharmaceutical industry, Chagas, TC

Chagas disease is one of five Neglected Parasitic Infections prioritized by the Centers for Disease Control and Prevention.

Key Points: 
  • Chagas disease is one of five Neglected Parasitic Infections prioritized by the Centers for Disease Control and Prevention.
  • Chagas disease infection can cause cardiac arrhythmias and heart failure, leading to over 50,000 deaths per year worldwide.
  • The annual economic burden of Chagas disease is estimated at over $7 billion.
  • Dr. Gargs lab developed a novel DNA-based vaccine to protect against Tc infection, which was tested in preclinical models in combination with 7HPs lead, clinical-stage oral immunostimulant.

Cytokinetics Announces Additional Results From REDWOOD-HCM to Be Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions

Retrieved on: 
Friday, June 3, 2022
ASE, Facebook, Adult, Intellectual property, Cytokinetics, Research, American Society of Echocardiography, Society, Patent, LinkedIn, UCSF, Security (finance), YouTube, U.S. Securities and Exchange Commission, Amyotrophic lateral sclerosis, Heart failure, Clinical study design, Pharmacology, University, Sale, FDA, Safe harbor, GLOBE, Patient, Private Securities Litigation Reform Act, ALS, SAN, Twitter, Department, FACC, History, Muscle weakness, The Act, Mechanics, Act, Sarcoidosis, University of California, Hospital, Pharmaceutical industry, Echocardiography, Chagas, Amyloidosis, HCM

A recording of the presentation will be available on-demand for registered attendees starting July 11, 2022 at 10:00 AM ET.

Key Points: 
  • A recording of the presentation will be available on-demand for registered attendees starting July 11, 2022 at 10:00 AM ET.
  • Cytokinetics' research and development activities; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits of Cytokinetics' other drug candidates.
  • For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.
  • CYTOKINETICS and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Texas Heart Institute, University of Texas Medical Branch (UTMB) and 7 Hills Pharma Pioneer Significant Vaccine Research

Retrieved on: 
Friday, October 1, 2021
Antigen presentation, Regenerative medicine, U.S. News & World Report, The Texas Heart Institute, Chagas, Population, COVID-19 vaccine, University, Cardiovascular disease, UTMB, Vaccine, U, Chagas disease, Heart failure, Texas A&M University, Degenerative disease, Parasitism, Research, Trypanosoma cruzi, Stroke, Physician, Central nervous system, Heart, CEO, Awareness, Disease, Cardiology, Marathi, Vaccination, THI, Infection, Therapy, FDA, Health, Cell adhesion, PD-1, Risk, Organization, Education, GLOBE, Use, News, Patient, List of Nature Research journals, COVID-19, Antigen, Integrin, Howard Brody, Pharmaceutical industry, Medical imaging

Chagas is endemic in Latin America and Mexico and causes damage to the heart and to the central nervous system.

Key Points: 
  • Chagas is endemic in Latin America and Mexico and causes damage to the heart and to the central nervous system.
  • It is estimated that over 300,000 people in the United States and over 8 million worldwide are afflicted with Chagas Disease.
  • Specifically, in Texas, scientists at Texas A&M University have been studying Chagas Disease in kissing bugs since 2012 and found that 55% of over 7,000 bugs studied possessed the aforementioned parasite that causes the illness.
  • While not an overtly common ailment, Chagas is a very serious disease that can cause heart failure and stroke with lethal consequences, Dr. Woodside emphasized.

U.S. Food and Drug Administration Approves Lampit® (nifurtimox) for the Treatment of Chagas Disease in Children

Retrieved on: 
Friday, August 7, 2020
General Health, FDA, Infectious diseases, Health, Pharmaceutical, Infectious diseases, Medical specialties, RTT, Antiprotozoal agents, Neglected tropical diseases, Chagas disease, Nifurtimox, Chagas, General Health, FDA, Infectious diseases, Health, Pharmaceutical, Infectious diseases, Medical specialties, RTT, Antiprotozoal agents, Neglected tropical diseases, Chagas disease, Nifurtimox, Chagas

The importance of treating children is a major reason behind Bayers collaboration with health authorities to enhance access to Lampit as a means to provide treatment for Chagas disease.

Key Points: 
  • The importance of treating children is a major reason behind Bayers collaboration with health authorities to enhance access to Lampit as a means to provide treatment for Chagas disease.
  • The FDA approval is based on results from the Chagas disease in children treated with nifurtimox study, the first part of the largest Phase III program ever conducted in pediatric patients for the treatment of Chagas disease.
  • The hypersensitivity could be a reaction induced by nifurtimox or an immune response triggered by Chagas disease during treatment.
  • Making treatment safer and more effective for people living with Chagas disease: an update on DNDis Chagas disease portfolio.

Chagas Disease Pipeline Insight, 2020: Therapeutic Assessment, Unmet Needs, Products, Drugs, Companies - ResearchAndMarkets.com

Retrieved on: 
Friday, May 1, 2020
Health, Pharmaceutical, Infectious diseases, Medicine, Medical specialties, Tropical diseases, Neglected diseases, RTT, Chagas disease, Zoonoses, Chagas, Disease, Therapeutic assessment

A detailed picture of the Chagas Disease pipeline landscape is provided, which includes the disease overview and Chagas Disease treatment guidelines.

Key Points: 
  • A detailed picture of the Chagas Disease pipeline landscape is provided, which includes the disease overview and Chagas Disease treatment guidelines.
  • The assessment part of the report embraces in-depth Chagas Disease commercial assessment and clinical assessment of the Chagas Disease pipeline products from the pre-clinical developmental phase to the marketed phase.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Chagas Disease treatment.
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Chagas Disease) includes therapeutic assessment and comparative analysis.

Bayer's Phase III Clinical Trial Of Nifurtimox In Pediatric Patients With Chagas Disease Meets Primary Endpoint

Retrieved on: 
Thursday, March 14, 2019
Infectious diseases, RTT, Chemistry, Medical specialties, Antiprotozoal agents, Nifurtimox, Benznidazole, Chagas disease, Carlos Chagas, Chagas

WHIPPANY, N.J., March 14, 2019 /PRNewswire/ --Bayer presented results today from the CHICO part (CHagas disease In Children treated with NifurtimOx) of the phase III clinical study of investigational nifurtimox in pediatric patients with Chagas disease at the "XV Taller sobre la enfermedad de Chagas" conference in Barcelona, Spain.

Key Points: 
  • WHIPPANY, N.J., March 14, 2019 /PRNewswire/ --Bayer presented results today from the CHICO part (CHagas disease In Children treated with NifurtimOx) of the phase III clinical study of investigational nifurtimox in pediatric patients with Chagas disease at the "XV Taller sobre la enfermedad de Chagas" conference in Barcelona, Spain.
  • CHICO was the first part of a prospective, randomized (to dosing regimen), double-blind, historically placebo controlled phase III trial to evaluate the efficacy, safety, and pharmacokinetics of nifurtimox in 330 pediatric patients with acute or chronic Chagas disease.
  • The treatment of Chagas disease is based on only two nitroheterocyclic compounds, nifurtimox and benznidazole.
  • Chagas disease is named after Carlos Ribeiro Justiniano Chagas, a Brazilian physician and researcher who discovered the disease in 1909.